Matthew Yglesias @mattyglesias
The non-Trump version of the story seems to be a disagreement inside the public health bureaucracy about the merits of approving a safe treatment whose effectiveness is unclear, part of a bigger debate about FDA procedures. https://t.co/OVBcMkjXr1 — PolitiTweet.org